HIGHLIGHTS
- who: Imma Forzano and collaborators from the University of Missouri, United States have published the article: The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension, in the Journal: (JOURNAL) of 30/07/2020
- how: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
SUMMARY
Aldosterone, baxdrostat, blood pressure, BrigHTN, CIN-107, clinical trial, hypertension, resistant hypertension Resistant hypertension is defined by blood pressure (BP) targets not achieved . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.